

Laura Gramantieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4879285/publications.pdf>

Version: 2024-02-01

104
papers

8,416
citations

66343

42
h-index

45317

90
g-index

106
all docs

106
docs citations

106
times ranked

10824
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma. , 2022, , 301-315.		0
2	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. <i>Nutrients</i> , 2022, 14, 1652.	4.1	6
3	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2022, 12, 930.	4.0	2
4	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. <i>Cells</i> , 2021, 10, 521.	4.1	13
5	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 369-385.	3.7	12
6	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4305-4308.	2.0	1
7	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 741-757.	3.7	29
8	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. <i>Cancers</i> , 2021, 13, 4550.	3.7	6
9	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	3.6	12
10	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2674.	3.7	13
11	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	7.0	13
12	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> / <i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2020, 80, 1720-1734.	0.9	47
13	Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. <i>Journal of Hepatology</i> , 2020, 72, 1159-1169.	3.7	38
14	Metformin prevents liver tumorigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. <i>Oncogene</i> , 2019, 38, 7035-7045.	5.9	55
15	Role of SIRT-3, p-mTOR and HIF-1 α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1503.	4.1	24
16	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 171.	2.4	37
17	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 239-250.	5.1	14
18	Brivanib in combination with Notch3 silencing shows potent activity in tumour models. <i>British Journal of Cancer</i> , 2019, 120, 601-611.	6.4	7

#	ARTICLE	IF	CITATIONS
19	Animal Models of Hepatocellular Carcinoma Prevention. <i>Cancers</i> , 2019, 11, 1792.	3.7	10
20	MicroRNAs in Animal Models of HCC. <i>Cancers</i> , 2019, 11, 1906.	3.7	25
21	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018, 120, 95-102.	1.8	22
22	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 4.	6.3	68
23	LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , 2018, 9, 35085-35099.	1.8	46
24	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364.	1.8	79
25	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 485-493.	5.1	81
26	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. <i>Oncotarget</i> , 2018, 9, 17895-17905.	1.8	6
27	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3 Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2017, 23, 3953-3965.	7.0	137
28	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 44685.	3.3	11
29	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2397-2407.	2.3	13
30	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 56.	4.1	35
31	Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. <i>Oncotarget</i> , 2016, 7, 32375-32393.	1.8	83
32	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2029.	4.1	26
33	The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. <i>Journal of Hepatology</i> , 2016, 64, 891-898.	3.7	34
34	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371.	1.8	45
35	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 39609-39626.	1.8	25
36	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. <i>PLoS ONE</i> , 2015, 10, e0141448.	2.5	113

#	ARTICLE	IF	CITATIONS
37	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 29.	3.7	26
38	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2015, , 89.	5.5	0
39	Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. <i>Hepatology</i> , 2015, 61, 249-259.	7.3	63
40	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. <i>Cell Death and Differentiation</i> , 2015, 22, 46-57.	11.2	140
41	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2014, 12, 203-216.	3.4	43
42	Significance of serum and hepatic microRNA-221 levels in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, e302-7.	3.9	124
43	The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 α Activity by Changing miR Expression Patterns in Human Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 239-248.	4.1	63
44	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 10607-10620.	1.8	39
45	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. <i>Frontiers in Genetics</i> , 2013, 4, 64.	2.3	42
46	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. <i>OncoTargets and Therapy</i> , 2013, 6, 1167.	2.0	56
47	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. <i>PLoS ONE</i> , 2013, 8, e73964.	2.5	53
48	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3 β phosphorylation and p21 down-regulation in hepatocellular carcinoma. <i>Oncotarget</i> , 2013, 4, 1618-1631.	1.8	42
49	CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2012, 181, 413-422.	3.8	58
50	In hepatocellular carcinoma miR-19d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. <i>Journal of Pathology</i> , 2012, 227, 275-285.	4.5	180
51	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033.	7.3	150
52	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2012, 48, 391-401.	5.5	29
53	From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , 2011, 6, 93-98.	2.0	25
54	MicroRNA response to environmental mutagens in liver. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 67-76.	1.0	24

#	ARTICLE	IF	CITATIONS
55	microRNA Involvement in Hepatocellular Carcinoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 500-521.	1.7	88
56	Mutated β -catenin evades a microRNA-dependent regulatory loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4840-4845.	7.1	48
57	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1319-1326.	2.3	20
58	MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2010, 70, 5184-5193.	0.9	389
59	Oncogenic Role of miR-483-3p at the IGF2/483 Locus. <i>Cancer Research</i> , 2010, 70, 3140-3149.	0.9	272
60	Correction: Online Publication Dates for <i>Cancer Research</i> April 15, 2010 Articles. <i>Cancer Research</i> , 2010, 70, 4785-4786.	0.9	0
61	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. <i>Clinical Cancer Research</i> , 2009, 15, 5073-5081.	7.0	298
62	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5761-5767.	0.9	380
63	Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. <i>Journal of Hepatology</i> , 2009, 50, 969-979.	3.7	87
64	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. <i>Laboratory Investigation</i> , 2008, 88, 995-1007.	3.7	21
65	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. <i>Oncogene</i> , 2008, 27, 5651-5661.	5.9	619
66	MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2189-2204.	3.6	248
67	Hepatocellular carcinoma: Epidemiology and clinical aspects. <i>Molecular Aspects of Medicine</i> , 2008, 29, 130-143.	6.4	92
68	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099.	0.9	782
69	Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 997-1007.	3.9	96
70	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. <i>Cancer Cell</i> , 2007, 12, 215-229.	16.8	681
71	Notch3 intracellular domain accumulates in HepG2 cell line. <i>Anticancer Research</i> , 2006, 26, 2123-7.	1.1	29
72	GADD45 expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. <i>Human Pathology</i> , 2005, 36, 1154-1162.	2.0	31

#	ARTICLE	IF	CITATIONS
73	Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer. <i>Cancer Research</i> , 2004, 64, 8156-8159.	0.9	96
74	Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. <i>Digestive and Liver Disease</i> , 2004, 36, 594-602.	0.9	2
75	Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. <i>Journal of Clinical Ultrasound</i> , 2003, 31, 387-391.	0.8	15
76	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. <i>Journal of Hepatology</i> , 2003, 39, 997-1003.	3.7	40
77	Multigene Methylation Analysis of Gastrointestinal Tumors. <i>Molecular Diagnosis and Therapy</i> , 2003, 7, 201-207.	1.1	18
78	Multigene Methylation Analysis of Gastrointestinal Tumors. <i>Molecular Diagnosis and Therapy</i> , 2003, 7, 201-207.	1.1	33
79	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. <i>Oncogene</i> , 2002, 21, 2564-2572.	5.9	52
80	Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation. <i>Free Radical Research</i> , 2002, 36, 939-948.	3.3	97
81	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. <i>Ultrasound in Medicine and Biology</i> , 2001, 27, 893-899.	1.5	66
82	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. <i>Gut</i> , 2001, 48, 251-259.	12.1	567
83	Serum Xanthine Oxidase in Human Liver Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 1194-1199.	0.4	49
84	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. <i>Journal of Medical Virology</i> , 2000, 62, 25-28.	5.0	24
85	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. <i>Hepatology</i> , 2000, 31, 349-357.	7.3	37
86	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. <i>Digestive Diseases and Sciences</i> , 2000, 45, 306-311.	2.3	5
87	Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. <i>American Journal of Gastroenterology</i> , 2000, 95, 3537-3546.	0.4	45
88	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5445-5449.	7.1	81
89	Imbalance of IL-1 β and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. <i>Clinical and Experimental Immunology</i> , 1999, 115, 515-520.	2.6	25
90	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. <i>Hepatology</i> , 1999, 30, 58-64.	7.3	141

#	ARTICLE	IF	CITATIONS
91	Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). <i>Clinica Chimica Acta</i> , 1999, 281, 147-158.	1.1	22
92	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
93	Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 475-481.	3.7	8
94	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. <i>American Journal of Gastroenterology</i> , 1998, 93, 1925-1930.	0.4	32
95	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 799-804.	1.6	31
96	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. <i>Journal of Hepatology</i> , 1997, 27, 979-985.	3.7	256
97	A case of extracranial vertebral artery dissection with spontaneous recovery. <i>European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology</i> , 1997, 6, 197-201.	1.3	2
98	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. <i>Ultrasound in Medicine and Biology</i> , 1997, 23, 675-682.	1.5	54
99	Possible mechanisms for changes of intrasplenic arterial impedance indices in portal hypertension. <i>Hepatology</i> , 1997, 26, 513-514.	7.3	9
100	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. <i>Journal of Hepatology</i> , 1996, 24, 60-65.	3.7	19
101	Alteration of DNA ploidy and cell nuclearity in human hepatocellular carcinoma associated with HBV infection. <i>Journal of Hepatology</i> , 1996, 25, 848-853.	3.7	8
102	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 800-808.	2.3	8
103	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 1115-1120.	2.8	17
104	Diagnostic and prognostic value of dna ploidy and cell nuclearity in ultrasound-guided liver biopsies. <i>Cancer</i> , 1994, 74, 1713-1719.	4.1	20